SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

LP-935509

Item No. 37283

CAS Registry No.:	1454555-29-3
Formal Name:	4-[3-(2-methoxy-3-pyridinyl) pyrazolo[1,5-a]pyrimidin-5-yl]-1-piperazinecarboxylic acid, 1-methylethyl ester
MF:	$C_{20}H_{24}N_6O_3$
FW:	396.4
Purity:	≥98%
UV/Vis.:	λ_{max}: 268, 308, 321 nm
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

LP-935509 is supplied as a solid. A stock solution may be made by dissolving the LP-935509 in the solvent of choice, which should be purged with an inert gas. LP-935509 is soluble in DMSO.

Description

LP-935509 is an inhibitor of AP2-associated protein kinase 1 (AAK1) and BMP2-inducible kinase (BIKe; IC_{50}s = 3.3 and 14 nM, respectively).[1] It is selective for AAK1 and BIKe over μ- and κ-opioid, as well as α_{2A}- and α_{2C}-adrenergic, receptors (IC_{50}s = >30 μM for all), α_1 and α_2 subunit-containing $GABA_A$ receptors (IC_{50}s = 12 μM for both), and cyclin G-associated kinase (GAK; IC_{50} = 0.32 μM). LP-935509 (1 μM) reduces phosphorylation of the synaptic vesicle regulator AP2 complex subunit Mu-1 (AP2M1) in SH-SY5Y neuroblastoma cells.[2] It reduces the number of formalin-induced flinches in mice when administered at doses of 10, 30, and 60 mg/kg.[1]

References

1. Kostich, W., Hamman, B.D., Li, Y.-W., *et al.* Inhibition of AAK1 kinase as a novel therapeutic approach to treat neuropathic pain. *J. Pharmacol. Exp. Ther.* **358(3)**, 371-386 (2016).
2. Liu, Q., Bautista-Gomez, J., Higgins, D.A., *et al.* Dysregulation ofthe AP2M1 phosphorylation cycle by LRRK2 impairs endocytosis and leads to dopaminergic neurodegeneration. *Sci. Signal.* **14(693)**, eabg3555 (2021).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM